LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

Search

Bristol-Myers Squibb Co.

Fermé

Secteur Soins de santé

42.62 0.47

Résumé

Variation du prix de l'action

24h

Actuel

Min

41.6

Max

42.81

Chiffres clés

By Trading Economics

Revenu

-14B

-12B

Ventes

423M

12B

P/E

Moyenne du Secteur

14.05

79.786

BPA

-4.4

Marge bénéficiaire

-100.092

Employés

34,100

EBITDA

-13B

-8.6B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+18.4 upside

Dividendes

By Dow Jones

Prochains Résultats

26 juil. 2024

Date du Prochain Dividende

1 août 2024

Date du Prochain Détachement de Dividende

3 oct. 2024

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

61M

82B

Ouverture précédente

42.15

Clôture précédente

42.62

Sentiment de l'Actualité

By Acuity

34%

66%

69 / 369 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Bristol-Myers Squibb Co. Graphique

Actualités Associées

25 avr. 2024, 14:38 UTC

Résultats

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

25 avr. 2024, 11:52 UTC

Résultats

Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss

18 mars 2024, 10:14 UTC

Principaux Mouvements du Marché

2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma

13 mars 2024, 18:16 UTC

Principaux Mouvements du Marché

2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy

11 mars 2024, 22:07 UTC

Résultats
Principaux Mouvements du Marché

CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate

19 juin 2024, 05:30 UTC

Actualités
Acquisitions, Fusions, Rachats

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28 mai 2024, 22:51 UTC

Market Talk
Acquisitions, Fusions, Rachats

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25 avr. 2024, 12:36 UTC

Résultats

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

25 avr. 2024, 12:31 UTC

Acquisitions, Fusions, Rachats

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market -- IBD

25 avr. 2024, 11:31 UTC

Résultats

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags -- IBD

25 avr. 2024, 11:06 UTC

Résultats

Bristol-Myers Squibb Still Sees 2024 Total Revenue Up Low-Single Digits >BMY

25 avr. 2024, 11:05 UTC

Résultats

Bristol-Myers Squibb Cuts 2024 View To EPS 40c-EPS 70c >BMY

25 avr. 2024, 11:05 UTC

Résultats

Bristol-Myers: Prioritizing Investing in Key Growth Brands, Optimizing Operations Across Organization >BMY

25 avr. 2024, 11:04 UTC

Résultats

Bristol-Myers: Focusing Resources on R&D Programs With Potential to Deliver Greatest Return on Investment >BMY

25 avr. 2024, 11:04 UTC

Résultats

Bristol-Myers: Executing Strategic Productivity Initiative Aimed at $1.5B Cost Savings by End 2025 >BMY

25 avr. 2024, 11:03 UTC

Résultats

Bristol-Myers Squibb 1Q Adjusted Gross Margin 75.5% >BMY

25 avr. 2024, 11:03 UTC

Résultats

Bristol Myers Squibb Reports Narrower-Than-Expected First-Quarter Loss, Sales Top Estimates -- MarketWatch

25 avr. 2024, 11:03 UTC

Résultats

Bristol-Myers Squibb 1Q International Revenue Relatively Flat at $3.4B >BMY

25 avr. 2024, 11:02 UTC

Résultats

Bristol-Myers Squibb 1Q U.S. Revenue Rose 7% to $8.5B >BMY

25 avr. 2024, 11:02 UTC

Résultats

Bristol-Myers Squibb: $6.30/Share 1Q Impact From Acquired IPRD Charge, Licensing Income >BMY

25 avr. 2024, 11:00 UTC

Résultats

Bristol-Myers Squibb 1Q Growth Portfolio Revenue $4.8B, Up 8% >BMY

25 avr. 2024, 10:59 UTC

Résultats

Bristol-Myers Squibb 1Q Loss/Shr $5.89 >BMY

25 avr. 2024, 10:59 UTC

Résultats

Bristol-Myers Squibb 1Q Rev $11.9B >BMY

25 avr. 2024, 10:59 UTC

Résultats

Bristol-Myers Squibb 1Q Adj Loss/Shr $4.40 >BMY

25 avr. 2024, 10:59 UTC

Résultats

Bristol-Myers Squibb 1Q Loss $11.91B >BMY

4 avr. 2024, 05:00 UTC

Actualités

Big Pharma Stocks Need a Rethink. Investors Keep -2-

4 avr. 2024, 05:00 UTC

Actualités

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake. -- Barrons.com

19 mars 2024, 15:00 UTC

Acquisitions, Fusions, Rachats

Fusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover -- IBD

18 mars 2024, 12:44 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics

26 févr. 2024, 13:35 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb Completes Acquisition Of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform >BMY

Comparaison

Variation de prix

Bristol-Myers Squibb Co. prévision

Objectif de Prix

By TipRanks

18.4% hausse

Prévisions sur 12 Mois

Moyen 50.19 USD  18.4%

Haut 75 USD

Bas 33.1 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

18 ratings

5

Achat

11

Maintien

2

Vente

Score Technique

By Trading Central

41.12 / 44.235Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

69 / 369Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.